Behavioral studies have suggested that (p-ClPhSe) 2 elicits an anorectic-like action in rats by inducing multiple effects such as satiety-enhancing effect, malaise and specific flavor; however, the molecular mechanisms underlying its anorexigenic action remain unclarified. Here, male Sprague-Dawley rats received acute and subchronic intraperitoneal treatments with (p-ClPhSe) 2 ; thereafter, in vivo and ex vivo analyses were carried out. The present study reveals that the reduction of food intake resulting from a single treatment with (p-ClPhSe) 2 (1 mg/kg, i.p.) was associated with decreased hypothalamic levels of pro-melanin-concentrating hormone (pro-MCH) and orexin precursor. In addition, repeated administrations of (p-ClPhSe) 2 (10 mg/kg; i.p.) for 7 days induced sustained food intake suppression, body weight loss and white fat reduction. Measurements of brown adipose tissue content and temperature as well as data obtained from a pair-fed group indicated that the effects of (p-ClPhSe) 2 on the body weight are closely related to its anorexigenic actions, ruling out the possibility of increased thermogenesis. Furthermore, (p-ClPhSe) 2 reduced the hypothalamic orexin precursor levels when repeatedly administered to rats. Sub-chronic treatment with (p-ClPhSe) 2 caused a decrease of serum triglyceride levels and down-regulation of hepatic cholesterol content. Therefore, the current study characterized the anorectic and reducing body weight actions of (p-ClPhSe) 2 in Sprague-Dawley rats. Besides, the set of results suggests that food intake suppressant effects triggered after (p-ClPhSe) 2 administration to rats are mainly related with the lower orexin levels in hypothalamus after acute and sub-chronic treatments.
Introduction
Studies have suggested that selenium (Se) is a micronutrient with potential use in the prevention and treatment of diseases (Weekley and Harris, 2013) . Se has demonstrated beneficial actions on insulin resistance in people with central obesity (Alizadeh et al., 2012) and insulin-like actions in diabetic rats (Battell et al., 1998; Douillet et al., 1998) . A recent study has reported negative associations between dietary Se intake and obesity measurements suggesting that high Se intake is associated with a healthy body composition profile (Wang et al., 2016) . Besides, Se supplementation is effective in inhibiting adipocyte hypertrophy and abdominal fat accumulation in OLETF rats (Kim et al., 2012) .
Se organic forms generally are more bio-available than the inorganic forms (Doucha et al., 2009 ) and efforts have been directed towards the synthesis of stable organoselenium compounds with pharmacological applications Nogueira et al., 2004; Soriano-Garcia, 2004) . In this regard, diphenyl diselenide [(PhSe) 2 ] has shown hypolipidemic (da de Bem et al., 2009 ), insulin-mimetic effects (Barbosa et al., 2008) and potential in reducing fat deposits (da Rocha et al., 2011) in laboratory animals. In addition, its parent compound, p-chloro-diphenyl diselenide [(pClPhSe) 2 ], has homeostatic effects on glucose metabolism and mitochondrial function alterations induced by monosodium glutamate in rats (Quines et al., 2016) and reverses metabolic dysfunction in rats fed with fructose (Quines et al., 2017b) . In addition to the biological activities described for diselenides in rodents, an experimental study reported that systemic administration of (PhSe) 2 or (p-ClPhSe) 2 in Wistar rats induces anorexigenic effects associated to a satiety-enhancing action (Bortolatto et al., 2015a) suggesting that additional experiments should be driven to investigate their anti-obesity potential. In this sense, a behavioral study which employed diets supplemented with (p-ClPhSe) 2 was carried out to gain better knowledge of the anorectic-like action of (p-ClPhSe) 2 . In fact, the anorexigenic action of (p-ClPhSe) 2 seems to be related to a satiating action as well to a specific flavor of (p-ClPhSe) 2 when mixed in the food and the development of aversive reactions after its consumption (Bortolatto et al., 2015b) .
These reports (Bortolatto et al., 2015a (Bortolatto et al., , 2015b suggest that, at least in part, (p-ClPhSe) 2 might alter some central pathways to inhibit food intake. Among the numerous brain areas involved in feeding behavior, the hypothalamus occupies a key position as a center regulating energy homeostasis (Lopez et al., 2016) . It is structured in anatomically-defined nuclei, all of them interconnected, forming neuronal circuits via axonal projections that modulates a wide range of homeostatic functions, including feeding. Food intake is regulated at hypothalamic level by orexigenic and anorexigenic neuropeptides which are under the control of peripheral signals as leptin (Lopez et al., 2007) . In the arcuate nucleus, the first-order neurons containing orexigenic [neuropeptide Y and agouti-related peptide (NPY/AGRP)] and anorexigenic [proopiomelanocortin and cocaine-and amphetamine-regulated transcript (POMC/CART)] neuropeptides project to the paraventricular nucleus (PVN) as well as to the lateral hypothalamus (LHA) and perifornical area (PFA), which are locations of second-order neurons involved in the regulation of feeding behavior and energy expenditure (Rojczyk et al., 2015; Schwartz et al., 2000; Valassi et al., 2008) . The known "feeding center" LHA, for instance, plays orexigenic function and expresses neuropeptides, such as orexin and melanin-concentrating hormone (MCH), which stimulate the eating behavior (Bonnavion et al., 2016; Sakurai, 2014) .
Currently, central molecular events triggered after (p-ClPhSe) 2 treatment are almost unknown. So far, it is known that the satiating action of (p-ClPhSe) 2 in rats is partially mediated by inhibition of hypothalamic serotonin (5-hydroxytryptamine, 5-HT) uptake (Bortolatto et al., 2015a ) with a supposed increase of the levels of this neurotransmitter in the synaptic cleft. The biogenic amines dopamine, norepinephrine and 5-HT can be regarded as central transducers of peripheral signaling at the hypothalamic level (Brunetti et al., 2012) by interacting with neuropeptides and hormones in this area (Kalra et al., 1999) . This idea is reinforced by Ferrante and collaborators through the investigation of central inhibitory effects on feeding caused by the adipo-myokine irisin in rats (Ferrante et al., 2016b) .
Therefore, the aim of this study was to extend the knowledge about the (p-ClPhSe) 2 effects in reducing the food intake and the body weight of rats by investigating particularly the hypothalamic molecular mechanisms regulating its satiety-enhancing action.
Material and methods

Animals
The experiments were carried out using male adult Sprague Dawley rats (200-280 g; 8-to 10-week-old rats) which were initially housed in cages (4 rats per cage) with free access to water and standard laboratory chow. A total of 102 rats were used for experiments. They were kept in a separate animal room, under conditions of controlled temperature (23°C) and illumination (12 h light/12 h dark cycle). The present experimental study was approved by the Ethics Committee of the University of Santiago de Compostela, in accordance with EU guidelines for the use of experimental animals as well as by the Institutional Ethics Committee on Care and Use of Experimental Animal Resources from the Federal University of Santa Maria-RS -Brazil and registered under the number 050/2012.
Chemicals
The organoselenium compound (p-ClPhSe) 2 was prepared and characterized based on a previous study (Paulmier, 1986) . 1 H and 13 C Nuclear Magnetic Resonance Spectroscopy analysis showed analytical and spectroscopic agreement with the assigned structure. The chemical purity of (p-ClPhSe) 2 (99.9%) was determined by gas chromatographymass spectrometry (Shimadzu QP2010PLUS GC/MS combination). Mineral oil was used as vehicle for (p-ClPhSe) 2 .
Acute experiments
The screening for drug effects on food intake was initially performed in a dose-response assessment over time (n = 10 rats/group). For this, rats were housed in individual cages with free access to water and habituated to 18 h of fasting for one week to obtain a regular food intake during the light phase. The groups were matched according to food intake and body weight. On the test day, rats fasting for 18 h (Farhang et al., 2010) were intraperitoneally (i.p.) treated with mineral oil (vehicle; 1 ml/kg) or (p-ClPhSe) 2 (0.1-10 mg/kg; 1 ml/kg) 30 min before the test. Cumulative food intake was measured 1, 8, 24 and 48 h after the eating period started in each cage.
After selecting appropriate time and dose for subsequent acute treatments, non-deprived rats were treated with vehicle or (p-ClPhSe) 2 at a dose of 1 mg/kg. Twenty-four h later, rats were weighed and then decapitated without anesthesia in order to extract the hypothalamus which was frozen immediately on dry ice, and kept at −80°C until processing the western blotting analysis (n=7 rats/group).
Sub-chronic experiments
Non-deprived rats were i.p. treated with vehicle or (p-ClPhSe) 2 at doses of 1 and 10 mg/kg for seven consecutive days, once a day in the morning; the food intake and body weight were daily registered (n=8 rats/group; 4 rats/cage). On the 7th day, rectal and brown adipose tissue (BAT) temperatures as well as body composition were checked. Immediately after these procedures, rats received the last drug administration and 2 h later they were decapitated for the collection of serum, liver and hypothalamus which were kept at −80°C until the analyses (western blotting or biochemical measurements). The BAT and epididymal white adipose tissue (eWAT) were also extracted and weighed.
An additional repeated experiment was performed employing an effective dose of (p-ClPhSe) 2 (10 mg/kg; i.p.) and a pair-fed group; and the food intake and body weight were daily checked (n=8 rats/group; 1 rat/cage). The pair-feeding regimen started 24 h after the first (pClPhSe) 2 treatment but lasted the same experimental period.
A sub-chronic treatment (7 days) with (p-ClPhSe) 2 was chosen for repeated administrations because previous studies have indicated its effectiveness in reducing the food intake and body weight (Bortolatto et al., 2015a) as well as in causing beneficial effects in an obesity model induced by monosodium glutamate in rats (Quines et al., 2017a (Quines et al., , 2016 . Besides, a 7-day treatment with (p-ClPhSe) 2 has also been related to other pharmacological actions in rodents as memory improvement (Bortolatto et al., 2012; Zborowski et al., 2016) .
Temperature measurements
Rectal temperature was recorded with a probe connected to digital thermometer (BAT-12 Microprobe-Thermometer; Physitemp; NJ, US); three measurements were performed for each rat and an average temperature was registered.
Interscapular temperature surrounding BAT was recorded with an infrared camera (Compact-Infrared-Thermal-Imaging Camera E60bx, FLIR, West Malling, Kent, UK) and analyzed with a specific software package (FLIRTools Software). For each rat, three pictures were taken and analyzed in a defined interscapular area to obtain an average temperature.
Body composition
The variation of the amount of fat mass and non-fat mass (lean mass) was measured through nuclear magnetic resonance imaging (Whole Body Composition Analyzer; Echo MRI, Houston, TX). Each rat was analyzed three times in order to obtain an average data; the procedure was performed at baseline conditions and once more on the 7th day of experiment.
Serum biochemical analyses
Quantitative determination of triglycerides, total cholesterol, NEFAS, glucose, aspartate transaminase (AST) and alanine transaminase (ALT) of each sample was measured in duplicate using commercial assay kits (Spinreact).
Liver fat extraction and determination
The extraction procedure was adapted from methods described previously (Nogueiras et al., 2009; Porteiro et al., 2013) . Liver tissue (~0.05 g) was homogenized in Tissue Lyser (QIAGEN) for 3 min at 22 Hz with a chloroform-methanol mix (2:1). Afterwards, the samples were shaken during 3 h at room temperature. For phase separation, distilled water (300 µl) was added; samples were centrifuged (30 min, 13.2 rpm, 25°C) and the organic lower layer was collected. The solvent was dried overnight and the organic residue was re-dissolved in chloroform (500 µl). The levels of triglycerides, total cholesterol and nonesterified fatty acids (NEFAS) of each sample were measured in duplicate after evaporation of the organic solvent using commercial assay kits (Spinreact).
Western blotting analysis
Western blotting was performed as previously described . Briefly, total protein lysates from hypothalamus (20 µg) were subjected to SDS-PAGE, electrotransferred onto a polyvinylidenedifluoride membrane, and probed with the following antibodies: BiP (GRP78) and phospho-CREB (Ser133) (p-CREB) (Cell Signaling technology, Danvers, Massachusetts); IRE1 alpha (IRE1) (Novus Biologicals); CART, Orexin-A/B (Orexin precursor), pro-MCH, p-PERK (Thr 981), GADD 153 (CHOP), CREB-1, eIF2α, HSP 90α/β (HSP 90), POMC, p-eIF2α, SIRT1 and XBP-1 (Santa Cruz Biotechnology, Santa Cruz, California); NPY, β-Actin (Sigma-Aldrich, St. Louis, MO); AGRP and IRE1 (Abcam). For protein detection, we used horseradish peroxidase-conjugated secondary antibodies (Dako, Glostrup, Denmark) and chemiluminescence (Pierce ECL Western Blotting Substrate; Thermo Scientific, Rockford, Illinois). Membranes were then exposed to X-ray film (Super RX, Fuji Medical X-Ray Film; Fujifilm, Tokyo, Japan) and developed with developer and fixing liquids (AGFA, Mortsel, Belgium) under appropriate dark-room conditions. Protein levels were normalized to β-actin or HSP 90 for each sample.
Statistical analysis
Data are expressed as mean ± standard error of the mean (S.E.M) and analyzed by GraphPad Prism (version 5). To test a Gaussian distribution, a D′Agostino-Pearson omnibus normality test was used. To compare pair experimental groups, an unpaired-t-test was used. Statistical comparisons among more experimental groups were performed using one-way analysis of variance (ANOVA) or the KruskalWallis test according to the parametric and non-parametric data, respectively. Two-way ANOVA followed by the Bonferroni post-test was employed for detecting treatment x time interactions for food intake and body weight concerning the repeated treatments with (p-ClPhSe) 2 . A value of P < 0.05 was considered significant.
Results
Acute experiments
3.1.1. Effects of a single (p-ClPhSe) 2 treatment on food intake and body weight A dose-response assessment over time for acute effects of (p- Fig. 1 . Effects of a single injection of (p-ClPhSe) 2 (0.1-10 mg/kg; i.p.) on cumulative food intake (A) and body weight change after 48 h (B) in fasted rats. The panel C illustrates the body weight change 24 h after the administration of the selected dose of (p-ClPhSe) 2 (1 mg/kg; i.p.) in nondeprived rats. Data analysis was carried out through (*) oneway ANOVA followed by the Newman-Keuls post-test, (**) the Kruskal-Wallis test or (***) the unpaired t-test according to data distribution. Significance: P < 0.05 as compared with the control group.
ClPhSe) 2 on food intake and body weight of fasted rats was performed (Fig. 1) . We found that (p-ClPhSe) 2 at a dose of 10 mg/kg suppressed food intake after 1, 8, 24 and 48 h whereas rats treated with 1 mg/kg showed a reduced food intake at 24 h and 48 h. Moreover, an inspection at the end of the experiment revealed that rats treated with 1 and 10 mg/kg gained less body weight, in a dose-dependent manner, when compared to the control group [P < 0.0001] (Fig. 1B) . From these data, the dose of 1 mg/kg and 24 h-feeding test were selected for another acute experiment where non-deprived rats also showed body weight reduction [P = 0.0015] (Fig. 1C) .
3.1.2. Hypothalamic effects after a single injection of (p-ClPhSe) 2 Hypothalamic protein levels of pro-MCH (pro-melanin-concentrating hormone) [P = 0.0176] and orexin precursor [P < 0.001] were down-regulated 48 h after a single injection of (p-ClPhSe) 2 (1 mg/ kg), whereas NPY (neuropeptide Y) was increased [P = 0.002]. The levels of CART, POMC and AgRP remained unaltered after acute (pClPhSe) 2 treatment ( Fig. 2A) .
In addition, the hypothalamic protein contents of p-CREB/CREB (cAMP response element binding protein) and SIRT1 (sirtuin 1) were unaffected by (p-ClPhSe) 2 treatment (Fig. 2B) .
Similarly, our results demonstrated that the hypothalamic protein levels related to the ER stress as BiP (binding of immunoglobulin protein), p-PERK (protein kinase R-like endoplasmic reticulum kinase), XBP1s (X-box-binding protein 1), CHOP (C/EBP homologous protein), p-IRE1/IRE1 (inositol-requiring enzyme 1) and p-eIF2α/eIF2α (eukaryotic initiation factor 2 alpha) remained unaltered after a single (p-ClPhSe) administration to rats (Fig. 2C). 3.2. Sub-chronic experiments 3.2.1. Effects of sub-chronic treatment with (p-ClPhSe) 2 on food intake and body weight
The repeated injection of (p-ClPhSe) 2 (1 and 10 mg/kg/d, i.p.) during 7 days revealed a significant reduction on average daily food intake in those animals treated with the highest dose of the compound [F (2,3) = 49.44; P = 0.0051] (Fig. 3A) . Besides, from the 2nd measurement onwards (p-ClPhSe) 2 at a dose of 10 mg/kg significantly reduced the body weight gain in comparison with that of the control group [F (10,105) = 22.38; P < 0.0001] (Fig. 3B) .
Because (p-ClPhSe) 2 caused a marked anorectic effect, we next assessed if the reduced weight gain was dependent on the food intake. To test this hypothesis, we performed an experimental paradigm using rats pair-fed to the amount of food eaten by (p-ClPhSe) 2 rats. We confirmed that a dose of (p-ClPhSe) 2 (10 mg/kg) reduced food intake throughout the entire experimental period as compared with the control group [F (5,70) = 2.678; P = 0.0284] (Fig. 3C ). In addition, the cumulative body weight change observed in rats belonging to the pair-fed group was similar to that of the (p-ClPhSe) 2 group and lower than the control group [F (10,105) = 9.755; P < 0.0001] (Fig. 3D) . Therefore, these results indicate that the suppression of weight gain induced by (pClPhSe) 2 is sufficiently explained by its anorectic action. Fig. 2 . Effects of a single injection of (p-ClPhSe) 2 (1 mg/kg; i.p.; 24 h) on protein levels of neuropeptides CART, POMC, NPY, AgRP, pro-MCH and orexin precursor (A); p-CREB/ CREB and SIRT1 (B); and ER stress-related proteins BIP, p-PERK, p-IRE1/IRE1, p-eIF2α/eIF2α, XBP-1 s and CHOP (C) in hypothalamus of non-deprived rats. HSP 90 or β-actin was used to normalize protein levels. Data analysis was carried out through (*) unpaired t-test. Significance: P < 0.05 as compared with the control group.
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European Journal of Pharmacology 815 (2017) 241-250 3.2.2. Effects of repeated administration of (p-ClPhSe) 2 on WAT and BAT contents, temperature measurements and body composition The eWAT/BW ratio of rats treated with (p-ClPhSe) 2 at the doses of 1 and 10 mg/kg for 7 days was lower in comparison with that of control rats [F (2,21) = 12.50; P = 0.0003] (Fig. 4A) . In addition, the data analysis regarding the body composition showed that rats receiving (pClPhSe) 2 at a dose of 10 mg/kg had less fat mass as compared with the control group [F (5,35) = 6.99; P = 0.0001] without alterations in the non-fat mass ( Fig. 4C and D, respectively) . No significant changes were found on BAT/BW ratio, rectal temperature and BAT interscapular temperature (Fig. B, E , F and G, respectively).
Hypothalamic effects after a sub-chronic treatment with (pClPhSe) 2
Hypothalamic protein levels of rats exposed to (p-ClPhSe) 2 (10 mg/ kg) for 7 days revealed a decrease in the orexin precursor levels [P = 0.0367] as well as an increase in the pro-MCH levels [P = 0.0451] as compared with the control group. The protein content of CART, POMC, NPY and AgRP did not change (Fig. 5A) . Furthermore, there were not alterations in the p-CREB/CREB and SIRT1 protein levels (Fig. 5B) .
Effects of repeated injections of (p-ClPhSe) 2 on serum and liver biochemical analysis
Quantitative analyses carried out in serum demonstrated that (pClPhSe) 2 at a dose of 10 mg/kg caused a decrease of triglycerides [F (2,21) = 9.564; P = 0.0011] and an increase of total cholesterol [F (2,21) = 8.509; P = 0.002] levels. The serum content of NEFAS and glucose remained unaltered after (p-ClPhSe) 2 treatment. In addition, no significant changes in the serum AST and ALT activities were detected in rats sub-chronically treated with (p-ClPhSe) 2 (Fig. 6) .
On the liver tissue, the repeated administration of (p-ClPhSe) 2 at both doses decreased the total cholesterol content [F (2,21) = 6.144; P = 0.0079], although no significant alterations were detected in liver triglycerides or NEFAS (Fig. 7) .
Discussion
This study describes for the first time the central molecular pathways associated with the anorexigenic and weight-reducing actions caused by (p-ClPhSe) 2 in male Sprague-Dawley rats. The pharmacological evidence for food intake suppressant effects of (p-ClPhSe) 2 is supported mainly by the modulation of hypothalamic neuropeptides involved in the appetite control and, more specifically, by the lower levels of the orexin precursor after a single and repeated administrations of (p-ClPhSe) 2 .
Data of the present study indicate that (p-ClPhSe) 2 elicited appetite suppressant effects in a dose-dependent manner when acutely administered to Sprague-Dawley rats. In addition, the sub-chronic treatment (7 days) with this organoselenium compound at a dose of 10 mg/ kg was effective in inducing sustained inhibition of food intake as well promoting body weight loss and reduction of total and epididymal white fat. Energy homeostasis depends upon the balance between Fig. 3 . Effects of sub-chronic treatment with (p-ClPhSe) 2 on food intake and body weight of rats. The panels A and B represent a dose-response assessment with the doses of 1 and 10 mg/ kg of (p-ClPhSe) 2 . The panels C and D represent an additional experiment employing an effective dose of (p-ClPhSe) 2 (10 mg/kg) and a pair-fed group. Data analysis was carried out through (*) the one-way ANOVA followed by the Newman-Keuls posttest or (+) the two-way ANOVA followed by the Bonferroni posttest. Significance: P < 0.05 as compared with the control group. caloric intake and energy expenditure and the last one can be affected by basal metabolism, physical activity and adaptive thermogenesis (Rosen and Spiegelman, 2006) . Here, through pair-feeding regimen we investigated if the lower weight gain resulting from (p-ClPhSe) 2 was dependent on food intake. Of note, the data showed that the body weight change of animals treated with (p-ClPhSe) 2 was similar to that of the pair-fed group supporting the hypothesis that the effects of (pClPhSe) 2 on body weight are closely related to its anorexigenic actions.
This hypothesis was further confirmed by analyzing BAT content and temperature measures, wherein the possible involvement of increased thermogenesis was ruled out. Although a sub-chronic treatment has been employed in the current study, future researches are required to determine the long-term (chronic) effects of (p-ClPhSe) 2 .
While many areas of the brain have demonstrated a key role in transmitting and integrating energy balance signals, the hypothalamus is the largest studied area. It is bordered by the third ventricle and the Fig. 4 . Effects of sub-chronic treatment with (p-ClPhSe) 2 (1 and 10 mg/kg; i.p.) on eWAT content (A), BAT content (B), total fat mass (EchoMRI) (C), non-fat mass (EchoMRI) (D), rectal temperature (E) and interscapular temperature surrounding BAT (Infrared thermal images) (F and G). Data analysis was carried out through (*) the one-way ANOVA followed by the Newman-Keuls post-test or (**) the one-way ANOVA with repeated measures. Significance: P < 0.05 as compared with the control or baseline groups. Abbreviations: BW -body weight.
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European Journal of Pharmacology 815 (2017) 241-250 highly vascularized median eminence, an area with a porous bloodbrain barrier. This makes it ideally positioned to sense and respond to a myriad of circulating hormones and nutrients (Donovan and Tecott, 2013; Rodriguez et al., 2010) . Feeding central regulation involves several signaling systems including hormones, monoamines, cannabinoids, opioids and specially anorexigenic (POMC and CART) and orexigenic (NPY, AgRP, MCH and orexins) neuropeptides among others (Lopez-Esparza et al., 2015; Pomorska et al., 2016; Waterson and Horvath, 2015) . It should be noted that POMC gene encodes both orexigenic β-endorphin and anorexigenic α-melanocyte-stimulating hormone (α-MSH) (Kalra et al., 1999) . We previously demonstrated that the inhibition of 5-HT uptake in hypothalamus seems to mediate part of the satiating action of (p-ClPhSe) 2 in rats (Bortolatto et al., 2015a) . 5-HT has been implicated in the control of eating behavior and body weight by inhibiting feeding at hypothalamic level (Leibowitz and Alexander, 1998) . Interestingly, an important interplay between the monoamines and the hypothalamic neuropeptides has been demonstrated by different studies (Brunetti et al., 2014; Ferrante et al., 2016a; Orlando et al., 2001 ). We then hypothesized that the (p-ClPhSe) 2 effects on food intake of rats could be also mediated by changes in hypothalamic neuropeptides.
In accordance with that, our results revealed a decrease of orexin precursor content in hypothalamus of rats which received acute and sub-chronic treatments with (p-ClPhSe) 2 . Orexins or hypocretins are multifunctional neuropeptides specially known for its regulatory function on sleep/wakefulness states and feeding behavior and expressed within the LHA (Sakurai, 2014) . In fact, prepro-orexin mRNA is upregulated when animals are fasted (Sakurai, 2014) . It has been reported the interaction between 5-HT and orexins. For instance, the 5-HT release from hypothalamic synaptosomes can be inhibited by orexins (Orlando et al., 2001) . Besides, anorexigenic action resulting from repeated peripheral administration of the adipokine chemerin (8 μg/kg) in rats is linked to an increase of hypothalamic 5-HT levels as well as reduction of relative gene expression of orexin-A (Brunetti et al., 2014) . Also, the increased food intake caused by apelin-13 administration into the ARC of rats seems to be related to inhibited 5-HT synthesis/release and increased orexin-A gene expression in the hypothalamus (Ferrante et al., 2016a) . Therefore, a reduction of orexin expression in hypothalamus could further explain the feeding suppressant action caused by single or repeated treatment with (p-ClPhSe) 2 and this effect could be associated to serotoninergic mechanisms.
Furthermore, a reduction of pro-MCH levels seems collaborate for the food intake suppressant action of a single administration of (pClPhSe) 2 in rats. MCH is also an orexigenic neuropeptide, which similar to orexins, underlies sleep-wake states, feeding, energy balance and motivated behavior in the LHA (Bonnavion et al., 2016) . A study carried out by Collin and colleagues showed the 5-HT(1 A) receptor immunoreactivity in MCH-and orexin-containing neurons, suggesting that 5-HT via postsynaptic 5-HT(1 A) receptors affects the release of peptides regulating food intake (Collin et al., 2002) . From the data presented here, we suggest that the modulation of LHA neuropeptides can be involved in the acute pharmacological actions of (p-ClPhSe) 2 on food intake. On the other hand, increased NPY and pro-MCH levels were observed in hypothalamus of rats treated with a single and repeated injections of (p-ClPhSe) 2 , respectively; which suggest that these findings derive from an attempt of the organism in reestablishing the energetic balance considering the very low food intake after (p-ClPhSe) 2 experience.
In addition to neuropeptide systems, we investigated if (p-ClPhSe) 2 could affect the expression of proteins which have been suggested to alter hypothalamic pathways that regulate food intake and body weight, such as CREB and SIRT1 (Cakir et al., 2009; Cyr et al., 2015; Ren et al., 2013) as well as ER stress markers (Hosoi et al., 2008; Schneeberger et al., 2013; Williams et al., 2014; Won et al., 2009 ). Ren and colleagues reported an inverse relationship between food intake and p-CREB protein levels in the brain regions involved in appetite regulation (Ren et al., 2013) . Besides, studies have shown that hypothalamic SIRT1 promotes positive energy balance (Cakir et al., 2009) and the blockade of SIRT1 activity can promote a negative energy balance and weight loss (Cyr et al., 2015) . However, the hypothalamic pCREB/CREB and SIRT1 protein levels were unaltered by (p-ClPhSe) 2 treatments ruling out the involvement of these mechanisms in anorectic and slimming actions induced by the compound. The term ER stress refers to the alterations of the protein-folding functionality of the ER (Martinez de Morentin et al., 2010) . Hypothalamic ER stress has been implicated as a pathogenic mechanism for obesity and associated Fig. 5 . Effects of sub-chronic treatment with (p-ClPhSe) 2 (10 mg/kg; i.p.) on hypothalamic protein levels of neuropeptides CART, POMC, NPY, AgRP, pro-MCH and orexin precursor (A); p-CREB/CREB and SIRT1 (B). HSP 90 or β-actin was used to normalize protein levels. Data analysis was carried out through (*) the unpaired t-test. Significance: P < 0.05 as compared with the control group. Fig. 6 . Effects of sub-chronic treatment with (p-ClPhSe) 2 (1 and 10 mg/kg; i.p.) on serum content of total cholesterol (A), triglycerides (B), NEFAs (C) , glucose (D), AST (E) and ALT (F) in rats. Data analysis was carried out through (*) the one-way ANOVA followed by the Newman-Keuls test. Significance: P < 0.05 as compared with the control group. Abbreviations: NEFAsnonesterified fatty acids. Fig. 7 . Effects of sub-chronic treatment with (p-ClPhSe) 2 (1 and 10 mg/kg; i.p.) on liver content of total cholesterol, triglycerides and NEFAs in rats. Data analysis was carried out through (*) the one-way ANOVA followed by the Newman-Keuls test. Significance: P < 0.05 as compared with the control group. Abbreviations: NEFAs -nonesterified fatty acids.
European Journal of Pharmacology 815 (2017) 241-250 disorders including diabetes mellitus (Williams et al., 2014; Won et al., 2009) . Considering the antioxidant properties of (p-ClPhSe) 2 (Meotti et al., 2004) , we examined if a reduction of ER markers could also mediate its appetite suppressant effects. Nevertheless, no significant changes were found on ER proteins in hypothalamus of rats which received a single dose of the organoselenium. Our results also show that (p-ClPhSe) 2 reduced the levels of liver cholesterol and serum triglycerides. The liver is the major site of cholesterol synthesis in mammals, although the intestine also forms significant amounts. An inhibitory effect of (p-ClPhSe) 2 on the hepatic de novo cholesterol biosynthesis could explain the present finding, but this hypothesis needs to be further investigated. However, a related point to consider is the fact that its parent compound, (PhSe) 2 , increases the content of phosphorylated 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) in HepG2 cell line indicating that (PhSe) 2 modulates the expression of some proteins involved in the cholesterol cell metabolism. Besides, (PhSe) 2 also reduced the serum triglycerides in rats and mice (Acker and Nogueira, 2014; da Rocha et al., 2011; Ribeiro et al., 2013) . Nevertheless, (p-ClPhSe) 2 caused an increase of serum cholesterol, an effect unexpected and poorly understood. Lastly, repeated administrations of (p-ClPhSe) 2 did not change serum AST and ALT activities (markers of liver function) in SpragueDawley rats which are consistent with results found in Swiss mice (Zborowski et al., 2016) .
Although the present study has supplied much useful information about the molecular mechanisms underlying the anorexigenic action of (p-ClPhSe) 2 , we acknowledge some limitations of this study. Here, the levels of orexin precursor were determined rather than the levels of orexins themselves. Although an increase in orexin precursor content suggests increments in orexin levels, a future study evaluating the impact of (p-ClPhSe) 2 treatment on orexin-A and -B levels can bring accurate details about its action. Besides, it was performed western blotting analyses without polymerase chain reaction (PCR) studies. In general, these techniques complement each other; however, we carried out here only the western blott analyses because this technique detects proteins with post-translational modification (e.g. phosphorylation of specific residues) involved in a signaling pathway.
Conclusions
In summary, the present study characterizes the anorectic and reducing body weight actions of (p-ClPhSe) 2 in male adult SpragueDawley rats. Besides, our data set suggests that acute and sub-chronic treatments with (p-ClPhSe) affect the levels of hypothalamic neuropeptides, decreasing the orexin precursor content. Therefore, this study provides evidence for the involvement of hypothalamic pathways in the regulation of the anorectic action of (p-ClPhSe) 2 in rats.
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